To elicit and value patient preferences for the processes and outcomes of surgical management of stress urinary incontinence in women.
A discrete choice experiment survey to elicit preferences for type of anaesthesia, postoperative recovery time, treatment success, adverse events, impact on daily activities and cost. An experimental design generated 40 choice tasks, and each respondent completed 1 block of 10 and 2 validity tests. Analysis was by multinomial logistical regression.
N=21 UK hospitals.
N=325 adult women who were a subsample of those randomised to the single-incision mini-slings clinical trial.
Patient preferences; valuation obtained using willingness to pay.
N=227 of 325 (70%) returned a questionnaire, and 94% of those completed all choice tasks. Respondents preferred general anaesthesia, shorter recovery times, improved stress urinary incontinence symptoms and avoidance of adverse events. Women were willing to pay (mean (95% CI)) £76 (£33 to £119) per day of reduction in recovery time following surgery. They valued increases in Patient Global Impression of Improvement, ranging from £8173 (£5459 to £10 887) for 'improved' to £11 706 (£8267 to £15 144) for 'very much improved' symptoms, compared with no symptom improvement. This was offset by negative values attached to the avoidance of complications ranging between £-8022 (£-10 661 to £-5383) and £-10 632 (£-14 077 to £-7187) compared to no complications. Women valued treatments that reduced the need to avoid daily activities, with willingness to pay ranging from £-967 (£-2199 to £266) for rarely avoiding activities to £-5338 (£-7258 to £-3417) for frequently avoiding daily activities compared with no avoidance.
This discrete choice experiment demonstrates that patients place considerable value on improvement in stress urinary incontinence symptoms and avoidance of treatment complications. Trade-offs between symptom improvement and adverse event risk should be considered within shared decision-making. The willingness to pay values from this study can be used in future cost-benefit analyses.
ISRCTN: 93264234; Post-results.
BMJ open. 2023 Aug 29*** epublish ***
Dwayne Boyers, Mary Kilonzo, Tracey Davidson, David Cooper, Judith Wardle, Kiron Bhal, James N'Dow, Graeme MacLennan, John Norrie, Mohamed Abdel-Fattah
Health Economics Research Unit, University of Aberdeen, Aberdeen, UK ., Health Economics Research Unit, University of Aberdeen, Aberdeen, UK., Health Services Research Unit, University of Aberdeen, Aberdeen, UK., Patient and Public Lead, Oxford, UK., University Hospital of Wales, Cardiff, UK., Academic Urology Unit, University of Aberdeen, Aberdeen, UK., Usher Institute, Edinburgh Clinical Trials Unit, University of Edinburgh No 9 Bioquarter, Edinburgh, UK., Aberdeen Centre for Women's Health Research, University of Aberdeen, Aberdeen, UK.